Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$6.31 +4.2%	$6.05	$4.47 ▼ $35.98	$6.67M	0.92	17,970 shs	13,087 shs
JBIO Jade Biosciences	$8.23 +11.5%	$8.70	$6.57 ▼ $105.00	$268.52M	1.03	118,290 shs	124,711 shs
PPBT Purple Biotech	$2.30 +1.3%	$2.37	$2.00 ▼ $13.95	$5.93M	0.49	36,580 shs	18,242 shs
SCNI Scinai Immunotherapeutics	$1.60 -7.5%	$2.00	$1.40 ▼ $6.18	$1.60M	1.86	3.25 million shs	222,325 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	0.00%	+15.69%	+2.52%	-10.95%	-51.87%
JBIO Jade Biosciences	0.00%	+11.82%	-1.20%	+822,999,900.00%	+822,999,900.00%
PPBT Purple Biotech	0.00%	-3.12%	-12.21%	-4.17%	+229,999,900.00%
SCNI Scinai Immunotherapeutics	0.00%	+0.63%	-25.23%	-41.82%	-63.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLM Apollomics	0.059 of 5 stars	0.0	3.0	0.0	0.0	0.0
JBIO Jade Biosciences	1.7756 of 5 stars	3.5	0.0	1.8	1.7	0.0
PPBT Purple Biotech	1.7075 of 5 stars	3.5	2.0	0.0	0.0	0.6
SCNI Scinai Immunotherapeutics	0.4583 of 5 stars	0.0	2.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	0.00	N/A	N/A	N/A
JBIO Jade Biosciences	3.00	Buy	$16.00	94.41% Upside
PPBT Purple Biotech	3.00	Buy	$33.00	1,334.78% Upside
SCNI Scinai Immunotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SCNI, APLM, JBIO, and PPBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $18.00
7/14/2025	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/16/2025	JBIO Jade Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	N/A	N/A	N/A	N/A	$4.48 per share	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.18 per share	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	$12.40 per share	N/A
SCNI Scinai Immunotherapeutics	$660K	2.42	N/A	N/A	$5.10 per share	0.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$53.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	-$69.63M	-$30.33	N/A	∞	N/A	N/A	-51.96%	-47.65%	N/A
PPBT Purple Biotech	-$7.24M	-$0.42	N/A	N/A	N/A	N/A	-14.00%	-12.52%	N/A
SCNI Scinai Immunotherapeutics	$4.80M	-$9.57	N/A	∞	N/A	N/A	N/A	-40.60%	N/A

Latest SCNI, APLM, JBIO, and PPBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	JBIO Jade Biosciences	-$0.43	-$0.86	-$0.43	-$0.86	N/A	N/A
8/6/2025	Q2 2025	PPBT Purple Biotech	-$0.21	-$0.40	-$0.19	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	N/A
SCNI Scinai Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	1.39	1.39
JBIO Jade Biosciences	N/A	10.31	10.31
PPBT Purple Biotech	N/A	2.88	2.88
SCNI Scinai Immunotherapeutics	0.06	1.32	1.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
JBIO Jade Biosciences	N/A
PPBT Purple Biotech	9.64%
SCNI Scinai Immunotherapeutics	58.41%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
JBIO Jade Biosciences	24.90%
PPBT Purple Biotech	2.98%
SCNI Scinai Immunotherapeutics	60.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	1.10 million	N/A	Not Optionable
JBIO Jade Biosciences	20	32.63 million	24.50 million	N/A
PPBT Purple Biotech	20	2.59 million	2.51 million	Optionable
SCNI Scinai Immunotherapeutics	20	1.00 million	391,000	Not Optionable

SCNI, APLM, JBIO, and PPBT Headlines

Recent News About These Companies

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

July 29, 2025 | prnewswire.com

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

June 12, 2025 | prnewswire.com

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

June 5, 2025 | prnewswire.com

Scinai Immunotherapeutics Reports Strong CDMO Growth

June 2, 2025 | tipranks.com

Scinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 30, 2025 | finanznachrichten.de

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 30, 2025 | prnewswire.com

Scinai Announces Annual Financial Results for 2024

May 7, 2025 | prnewswire.com

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

May 1, 2025 | prnewswire.com

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

March 27, 2025 | prnewswire.com

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

March 17, 2025 | prnewswire.com

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

March 5, 2025 | prnewswire.com

Scinai Immunotherapeutics Ltd. (SCNI)

January 28, 2025 | ca.finance.yahoo.com

Scinai Immunotherapeutics (NASDAQ: SCNI) to Engage Investors at January Conferences

January 7, 2025 | theglobeandmail.com

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

January 6, 2025 | prnewswire.com

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

December 16, 2024 | prnewswire.com

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

December 5, 2024 | prnewswire.com

Scinai Immunotherapeutics (NASDAQ: SCNI) Welcomes Dr. Jonathan Sadeh to Scientific Advisory Board

December 3, 2024 | theglobeandmail.com

There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability

November 29, 2024 | uk.finance.yahoo.com

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

November 27, 2024 | prnewswire.com

Scinai Immunotherapeutics Reports Financial Turnaround and Growth

November 26, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI, APLM, JBIO, and PPBT Company Descriptions

Apollomics NASDAQ:APLM

$6.30 +0.26 (+4.21%)

Closing price 08/22/2025 03:52 PM Eastern

Extended Trading

$6.04 -0.27 (-4.28%)

As of 08/22/2025 07:15 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Jade Biosciences NASDAQ:JBIO

$8.23 +0.85 (+11.52%)

As of 08/22/2025 04:00 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Purple Biotech NASDAQ:PPBT

$2.30 +0.03 (+1.32%)

Closing price 08/22/2025 03:53 PM Eastern

Extended Trading

$2.28 -0.02 (-0.91%)

As of 08/22/2025 07:35 PM Eastern

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Scinai Immunotherapeutics NASDAQ:SCNI

$1.60 -0.13 (-7.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.65 +0.05 (+3.37%)

As of 08/22/2025 07:58 PM Eastern

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time